July 1 (Reuters) - ATAI Life Sciences NV 9VC.DE:
ATAI LIFE SCIENCES AND BECKLEY PSYTECH ANNOUNCE POSITIVE TOPLINE RESULTS FROM THE PHASE 2B STUDY OF BPL-003 IN PATIENTS WITH TREATMENT-RESISTANT DEPRESSION
ATAI LIFE SCIENCES NV - STUDY SHOWS BPL-003 DEMONSTRATES RAPID, ROBUST AND DURABLE ANTIDEPRESSANT EFFECTS
ATAI LIFE SCIENCES NV: STUDY MET ITS PRIMARY AND ALL KEY SECONDARY ENDPOINTS
ATAI LIFE SCIENCES NV - BPL-003 WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS OR SUICIDE-RELATED SAFETY SIGNALS
Source text: ID:nGNX4pCjHv
Further company coverage: 9VC.DE
(((( Reuters.briefs@thomsonreuters.com ;));))